# Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Source: https://onco.cc/trials/nct06449313/  
OnCo record `nct06449313` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cemiplimab in lung cancer, run by Georgetown University, now recruiting.

## Summary

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features is a phase 2, interventional study registered as NCT06449313 by Georgetown University, with a registry enrolment figure of 21 participants, started 2026-08 and due to reach its primary completion in 2027-12. Interventions recorded: Cemiplimab-Rwlc. Conditions listed: Non-small Cell Lung Cancer Stage III. Primary outcome: Pathologic complete response (pCR) rate. Lung eligibility wording from the registry: "Histologically or cytologically confirmed stage 3 Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJCC) that meets one of the below criteria:". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: NEO-SURG
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06449313
- Phase: 2
- Setting: A Phase 2 Single-arm Study of Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement or Other High Risk Features
- Sponsor: Georgetown University
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT06449313: https://clinicaltrials.gov/study/NCT06449313

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06449313.json